Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Beconase Hayfever Nasal Spray Would Have Strong Safety Profile – GSK

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline Consumer Healthcare's Beconase Hayfever nasal spray has an appropriate safety profile for OTC use, the firm says in a Sept. 9 "consultation letter" filed with the UK Medicines Control Agency
Advertisement

Related Content

Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
Glaxo Beconase growth suppression is safety concern in Rx labeling.
Glaxo Beconase growth suppression is safety concern in Rx labeling.

Topics

Advertisement
UsernamePublicRestriction

Register

PS094537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel